Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge

M Law; T Maruyama; J Lewis; E Giang; AW Tarr; Zacharenia Stamataki; P Gastaminza; FV Chisari; IM Jones; RI Fox; JK Ball; Jane McKeating; NM Kneteman; DR Burton

doi:10.1038/nm1698

Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge

M Law, T Maruyama, J Lewis, E Giang, AW Tarr, Zacharenia Stamataki, P Gastaminza, FV Chisari, IM Jones, RI Fox, JK Ball, Jane McKeating, NM Kneteman, DR Burton

Immunology and Immunotherapy

Research output: Contribution to journal › Article › peer-review

441 Citations (Scopus)

Abstract

A major problem in hepatitis C virus (HCV) immunotherapy or vaccine design is the extreme variability of the virus. We identified human monoclonal antibodies (mAbs) that neutralize genetically diverse HCV isolates and protect against heterologous HCV quasispecies challenge in a human liver-chimeric mouse model. The results provide evidence that broadly neutralizing antibodies to HCV protect against heterologous viral infection and suggest that a prophylactic vaccine against HCV may be achievable.

Original language	English
Pages (from-to)	25-27
Number of pages	3
Journal	Nature Medicine
Volume	14
Issue number	1
DOIs	https://doi.org/10.1038/nm1698
Publication status	Published - 1 Jan 2008

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1038/nm1698

Mechanisms of Hepatitis C Virus Induced Hepatocyte Injury
McKeating, J. & Balfe, P.
Medical Research Council
1/10/09 → 30/09/12
Project: Research Councils

Cite this

@article{0b5609e8cf2f4380a48d0e64277db3c4,

title = "Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge",

abstract = "A major problem in hepatitis C virus (HCV) immunotherapy or vaccine design is the extreme variability of the virus. We identified human monoclonal antibodies (mAbs) that neutralize genetically diverse HCV isolates and protect against heterologous HCV quasispecies challenge in a human liver-chimeric mouse model. The results provide evidence that broadly neutralizing antibodies to HCV protect against heterologous viral infection and suggest that a prophylactic vaccine against HCV may be achievable.",

author = "M Law and T Maruyama and J Lewis and E Giang and AW Tarr and Zacharenia Stamataki and P Gastaminza and FV Chisari and IM Jones and RI Fox and JK Ball and Jane McKeating and NM Kneteman and DR Burton",

year = "2008",

month = jan,

day = "1",

doi = "10.1038/nm1698",

language = "English",

volume = "14",

pages = "25--27",

journal = "Nature Medicine",

issn = "1546-170X",

publisher = "Nature Publishing Group",

number = "1",

}

TY - JOUR

T1 - Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge

AU - Law, M

AU - Maruyama, T

AU - Lewis, J

AU - Giang, E

AU - Tarr, AW

AU - Stamataki, Zacharenia

AU - Gastaminza, P

AU - Chisari, FV

AU - Jones, IM

AU - Fox, RI

AU - Ball, JK

AU - McKeating, Jane

AU - Kneteman, NM

AU - Burton, DR

PY - 2008/1/1

Y1 - 2008/1/1

N2 - A major problem in hepatitis C virus (HCV) immunotherapy or vaccine design is the extreme variability of the virus. We identified human monoclonal antibodies (mAbs) that neutralize genetically diverse HCV isolates and protect against heterologous HCV quasispecies challenge in a human liver-chimeric mouse model. The results provide evidence that broadly neutralizing antibodies to HCV protect against heterologous viral infection and suggest that a prophylactic vaccine against HCV may be achievable.

AB - A major problem in hepatitis C virus (HCV) immunotherapy or vaccine design is the extreme variability of the virus. We identified human monoclonal antibodies (mAbs) that neutralize genetically diverse HCV isolates and protect against heterologous HCV quasispecies challenge in a human liver-chimeric mouse model. The results provide evidence that broadly neutralizing antibodies to HCV protect against heterologous viral infection and suggest that a prophylactic vaccine against HCV may be achievable.

U2 - 10.1038/nm1698

DO - 10.1038/nm1698

M3 - Article

C2 - 18064037

SN - 1546-170X

VL - 14

SP - 25

EP - 27

JO - Nature Medicine

JF - Nature Medicine

IS - 1

ER -

Broadly neutralizing antibodies protect against hepatitis C virus quasispecies challenge

Abstract

UN SDGs

Access to Document

Fingerprint

Projects

Mechanisms of Hepatitis C Virus Induced Hepatocyte Injury

Cite this